MA28079A1 - Antagonistes de l'hormone concentrant la melanine - Google Patents

Antagonistes de l'hormone concentrant la melanine

Info

Publication number
MA28079A1
MA28079A1 MA28903A MA28903A MA28079A1 MA 28079 A1 MA28079 A1 MA 28079A1 MA 28903 A MA28903 A MA 28903A MA 28903 A MA28903 A MA 28903A MA 28079 A1 MA28079 A1 MA 28079A1
Authority
MA
Morocco
Prior art keywords
melanine
concentrating
hormone antagonists
units
taken together
Prior art date
Application number
MA28903A
Other languages
English (en)
Inventor
Xiufeng Eric Hu
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA28079A1 publication Critical patent/MA28079A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

vii) R3a et R3b ou R4a et R4b peuvent être pris conjointement pour former un motif répondant à la formule: C=X, dans laquelle X représente O,S ou NR5; et viii) deux motifs R3b ou deux motifs R4b provenant d'atomes de carbone adjacents peuvent être pris conjointement pour former une double liaison; les indices m et n ayant chacun indépendamment une valeur de 0 à 5.
MA28903A 2003-10-01 2006-03-31 Antagonistes de l'hormone concentrant la melanine MA28079A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50777303P 2003-10-01 2003-10-01
US53664004P 2004-01-15 2004-01-15

Publications (1)

Publication Number Publication Date
MA28079A1 true MA28079A1 (fr) 2006-08-01

Family

ID=34426018

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28903A MA28079A1 (fr) 2003-10-01 2006-03-31 Antagonistes de l'hormone concentrant la melanine

Country Status (20)

Country Link
US (1) US7304065B2 (fr)
EP (1) EP1667958A2 (fr)
JP (1) JP2007508303A (fr)
KR (1) KR20060060047A (fr)
CN (1) CN101068773A (fr)
AR (1) AR045958A1 (fr)
AU (1) AU2004278352B2 (fr)
BR (1) BRPI0415051A (fr)
CA (1) CA2540826A1 (fr)
CO (1) CO5690589A2 (fr)
IL (1) IL174370A0 (fr)
IS (1) IS8360A (fr)
MA (1) MA28079A1 (fr)
MX (1) MXPA06003654A (fr)
NO (1) NO20061953L (fr)
PE (1) PE20050475A1 (fr)
RU (1) RU2006110272A (fr)
SG (1) SG146692A1 (fr)
TW (1) TW200526554A (fr)
WO (1) WO2005033063A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001160A1 (fr) * 2006-06-23 2008-01-03 The Procter & Gamble Company Antagonistes de l'hormone concentrant la mélanine
PL2041093T3 (pl) * 2006-06-28 2010-09-30 Glaxo Group Ltd Pochodne piperazynylowe użyteczne w leczeniu zaburzeń, którym pośredniczy receptor GPR38
RU2009117182A (ru) * 2006-10-06 2010-11-20 Тайсо Фармасьютикал Ко., Лтд. (Jp) Производное 1-нафтилалкилпиперидина
EP2144870A2 (fr) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Procedes de synthese et de purification de composes d'aminoalkyltetracycline
EP2025674A1 (fr) * 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2307377A1 (fr) * 2008-06-18 2011-04-13 Pfizer Limited Dérivés de nicotinamide
UY32443A (es) * 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
AR075401A1 (es) 2009-02-13 2011-03-30 Sanofi Aventis Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
EP2522657B1 (fr) * 2010-01-06 2016-08-03 Takeda Pharmaceutical Company Limited Dérivé d'indole

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206428A (en) * 1989-11-16 1993-04-27 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthalene derivatives and preparation thereof
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JPH08506817A (ja) 1993-02-12 1996-07-23 メルク エンド カンパニー インコーポレーテッド スピロ（２ｈ−１−ベンゾピラン−２，４′−ピペリジン）クラス▲ｉｉｉ▼抗不整脈薬
WO1994027597A1 (fr) * 1993-05-21 1994-12-08 Smithkline Beecham Corporation Acides imidazolyl-alcenoiques antagonistes du recepteur de l'angiotensine ii
EP0763034A1 (fr) 1994-05-28 1997-03-19 Smithkline Beecham Plc Derives amide a activite antagoniste par rapport a 5ht1d
DE4438029A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K N.N-disubstituierte Benzocycloalkylamine, ihre Salze mit verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
DE69608551T2 (de) * 1995-03-27 2001-01-18 Smithkline Beecham P.L.C., Brentford Bicyclische amin-derivate und ihre verwendung als antipsychotische wirkstoffe
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
WO1998038156A1 (fr) 1997-02-27 1998-09-03 Takeda Chemical Industries, Ltd. Composes amines, leur elaboration, et leur utilisation comme inhibiteurs de la production d'amyloide beta
EP1104754A1 (fr) * 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Nouveaux derives sulfonyle
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
PT1285651E (pt) 2000-04-28 2010-10-21 Takeda Pharmaceutical Antagonistas da hormona concentradora da melanina
EP1283199A4 (fr) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd Antagoniste de l'hormone de concentration de la melanine
HUP0302582A2 (hu) 2000-12-22 2003-12-29 Schering Corp. Piperidin MCH antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk elhízás kezelésére
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
US7544690B2 (en) 2001-10-01 2009-06-09 Taisho Pharmaceutical Co., Ltd. MCH receptor antagonists
AU2002337956B2 (en) 2001-10-25 2006-02-23 Schering Corporation MCH Antagonists for the treatment of obesity
US6664273B2 (en) 2001-11-26 2003-12-16 Schering Corporation Piperidine based MCH antagonists for treatment of obesity and CNS disorders
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
EP1451156A4 (fr) 2001-11-27 2005-05-25 Merck & Co Inc Composes 4-aminoquinoleines
US7348328B2 (en) 2001-12-04 2008-03-25 Schering Corporation MCH antagonists for the treatment of obesity
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2503405A1 (fr) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Traitement du syndrome x a l'aide de tetralines et d'indanes substitues
WO2004092116A1 (fr) 2003-04-10 2004-10-28 Amgen, Inc. Composes bicycliques presentant une affinite pour les recepteurs de la bradykinine et compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
AR045958A1 (es) 2005-11-16
RU2006110272A (ru) 2007-11-10
NO20061953L (no) 2006-06-13
SG146692A1 (en) 2008-10-30
CA2540826A1 (fr) 2005-04-14
KR20060060047A (ko) 2006-06-02
AU2004278352B2 (en) 2008-10-30
MXPA06003654A (es) 2006-06-05
WO2005033063A2 (fr) 2005-04-14
AU2004278352A1 (en) 2005-04-14
WO2005033063A3 (fr) 2007-03-22
IS8360A (is) 2006-03-17
TW200526554A (en) 2005-08-16
BRPI0415051A (pt) 2006-11-28
JP2007508303A (ja) 2007-04-05
PE20050475A1 (es) 2005-10-05
CO5690589A2 (es) 2006-10-31
IL174370A0 (en) 2006-08-01
US7304065B2 (en) 2007-12-04
EP1667958A2 (fr) 2006-06-14
CN101068773A (zh) 2007-11-07
US20050075324A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
Vijayakumar et al. Anti-inflammatory activity of (+)-usnic acid
USD502231S1 (en) Wave beam
WO2003020217A3 (fr) Nouveaux analogues de pyrazole agissant sur les recepteurs cannabinoides
ECSP045425A (es) COMPUESTOS HETEROCÍCLICOS QUE INHIBEN LA ADHESIÓN DE LEUCOCITOS MEDIADA POR INTEGRINAS a4
USD453837S1 (en) Chromatography vial
USD465283S1 (en) Chromatography vial
WO2003004480A3 (fr) Piperazines et diazepanes substitues
BR9712808A (pt) Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador
EA200401561A1 (ru) Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов
MY134129A (en) Polymorphs of an epothilone analog
ATE473243T1 (de) Humane monoklonale antikörper gegen das kostimulatorische signaltransduktionsmolekül ailim und pharmazeutische verwendungen davon
NO20025517D0 (no) Triazolderivater
WO2003039454A3 (fr) Inhibiteurs de la beta-secretase et leurs procede d'utilisation
WO2005113534A3 (fr) Antagonistes de chimiokines cxcr1 et cxcr2
NO20074419L (no) Anvendelse av endotelinreseptorantagonister for fremstilling av medikamenter for a bekjempe sykdom
BR9916318A (pt) Compostos bicìclicos
ATE264298T1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten
EP1016664A4 (fr) Composes thiophene condenses et leur utilisation en medecine
BR9912010A (pt) Polimorfo de um produto farmacêutico
BRPI0408295A (pt) uso de um composto
USD476179S1 (en) Claw foot column
EP1544194A4 (fr) Derive 4-(aryl substitue)-5-hydroxyisoquinolinone
DE59610175D1 (de) Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
BR9812443A (pt) 1-2-3-4-5-6-hexahidro-2,6-metano-3-benzazocin-10-óis substituìdos, processos para sua preparação e seu emprego como medicamentos
HRP20100080T1 (hr) Kombinacija koja sadrži kandesartan i rosuvastatin za liječenje ateroskleroze